Based on our findings in the three MLL-AF6 and the two other MLLr-AML cell lines, as well as genetic deletion in murine AML models, we concluded that SHARP1 plays an oncogenic role in MLL-AF6 AML cells. Here, KMT2A is linked to acute myeloid leukemia.